Results 141 to 150 of about 1,633 (196)

Pressurized intraperitoneal aerosol chemotherapy in advanced gastric cancer with peritoneal metastases: a comprehensive meta-analysis of feasibility, efficacy, and safety. [PDF]

Gastroenterol Rep (Oxf)
Chen R, Yang Z, Li R, Yang Y, Zheng J, Wang J, Li Y.   +6 more
europepmc   +1 more source

Gastrointestinal CancerEmerging treatment modalities for gastric cancer with peritoneal metastases: a systematic review. [PDF]

Oncologist
Tops-Welten MW, Galanos LJK, Creemers GJ, Luyer MDP, De Hingh IHJT, van Hellemond IEG.   +5 more
europepmc   +1 more source

Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Malignancies with Palliative and Bidirectional Intent. [PDF]

Cancers (Basel)
Marrelli D, Carbone L, Fusario D, Petrioli R, Poto GE, Grassi G, Piagnerelli R, Piccioni SA, Ricci C, Bianco MT, Mazzei MA, Lazzi S, Roviello F.   +12 more
europepmc   +1 more source

Long-term survival in peritoneal mesothelioma treated with 24 consecutive PIPACs. [PDF]

Pleura Peritoneum
Mehdorn M, Jansen-Winkeln B, Rhode P, Niebisch S, Moulla Y, Schönherr T, Plum PS, Lordick F, Thieme R, Stocker G, von Laffert M, Gockel I, Stelzner S.   +12 more
europepmc   +1 more source

Feasibility of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in a Rabbit Model of Peritoneal Metastases: PIPALIM Project. [PDF]

Ann Surg Oncol
Bardet SM, Perrin ML, David V, Yardin C, Chaunavel A, Durand K, Maillan G, Rouchaud A, Durand Fontanier S, Taibi A.   +9 more
europepmc   +1 more source

Pressurised Intraperitoneal Aerosolised Chemotherapy (PIPAC) for Gastric Cancer With Peritoneal Metastases: A Systematic Review by the PIPAC UK Collaborative [PDF]

Critical Reviews in Oncology/Hematology, 2022
INTRODUCTION: Gastric cancer with peritoneal metastases (GCPM) carries a poor prognosis. Pressurised Intraperitoneal Aerosolised Chemotherapy (PIPAC) offers pharmacokinetic advantages over intravenous therapy, resulting in higher chemotherapy ...
Sarah Gwynne, Richard Adams, C J Peters
exaly   +5 more sources

Current Practice of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Still Standardized or on the Verge of Diversification?

European Journal of Surgical Oncology, 2021
Background: PIPAC is a new treatment modality for peritoneal cancer which has been practiced and evaluated until very recently by few academic centers in a highly standardized manner.
Marc A Reymond, Beate Rau, Wim Ceelen
exaly   +4 more sources

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) as an Outpatient Procedure [PDF]

Pleura and Peritoneum, 2018
BackgroundPressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) is a drug-delivery method for patients with peritoneal metastasis (PM). The study objective was to investigate whether PIPAC is possible in an outpatient setting.MethodsData was extracted
Martin Graversen, Per Pfeiffer, Michael Bau Mortensen   +2 more
exaly   +5 more sources

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Gastric Cancer Peritoneal Metastases: Results From the Lithuanian PIPAC Program [PDF]

Cancers
Background: Peritoneal metastases (PM) of gastric cancer (GC) are considered a terminal condition, with reported median survival ranging from 2 to 9 months.
Martynas Luksta, Kestutis Strupas, Edita Baltruskeviciene   +2 more
exaly   +5 more sources

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) of Peritoneal Metastasis From Gastric Cancer: A Descriptive Cohort Study

Clinical and Experimental Metastasis, 2020
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) represents a novel approach to deliver intraperitoneal chemotherapy. We report our experience with PIPAC in patients with peritoneal metastasis (PM) from gastric cancer (GC). Data from GC patients (
Martin Graversen, Sönke Detlefsen, Signe Bremholm Ellebæk   +2 more
exaly   +2 more sources